Enhancement of Humoral and Cellular Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 by a Third Dose of BNT162b2 Vaccine in Japanese Healthcare Workers.

Autor:	Miyakawa K; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan., Kato H; Infection Prevention and Control Department, Yokohama City University Hospital, Kanagawa, Japan., Ohtake N; Advanced Medical Research Center, Yokohama City University, Kanagawa, Japan.; Bioscience Division, Research and Development Department, Tosoh Corporation, Tokyo Research Center, Kanagawa, Japan., Jeremiah SS; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan., Ryo A; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
Jazyk:	angličtina
Zdroj:	The Journal of infectious diseases [J Infect Dis] 2023 Jan 11; Vol. 227 (2), pp. 221-225.
DOI:	10.1093/infdis/jiac344
Abstrakt:	The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has raised concerns regarding vaccine effectiveness. We investigated humoral and cellular immune responses against SARS-CoV-2 in healthcare workers before and after a third (booster) dose of the BNT162b2 messenger RNA vaccine. It significantly enhanced both humoral and cellular immunity in previously uninfected individuals. However, cellular immunity was not enhanced in previously infected persons, suggesting that 3 antigenic stimuli by vaccination or natural infection reached a plateau of cellular immunity. Even with reinforced immunity to SARS-CoV-2, we confirmed several postbooster breakthrough cases caused by the Omicron variant. Competing Interests: Potential conflicts of interest. N. O. is a current employee of Tosoh Corporation. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu